Intratumoral heterogeneity in cancer progression and response to immunotherapy (original) (raw)

• Vitale, I. et al. Mutational and antigenic landscape in tumor progression and cancer immunotherapy. Trends Cell Biol. 29, 396–416 (2019).
  Article CAS PubMed Google Scholar
• Wang, J. et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48, 768–776 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Teixeira, V. H. et al. Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions. Nat. Med. 25, 517–525 (2019).
  Article CAS PubMed Google Scholar
• Sharma, A. et al. Non-genetic intra-tumor heterogeneity is a major predictor of phenotypic heterogeneity and ongoing evolutionary dynamics in lung tumors. Cell Rep. 29, 2164–2174(2019).
  Article CAS PubMed PubMed Central Google Scholar
• van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265–1281(2019).
  Article PubMed PubMed Central Google Scholar
• Grosselin, K. et al. High-throughput single-cell ChIP–seq identifies heterogeneity of chromatin states in breast cancer. Nat. Genet. 51, 1060–1066 (2019).
  Article CAS PubMed Google Scholar
• Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science 357, eaal2380 (2017).
  Article PubMed PubMed Central Google Scholar
• Costa, A. et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463–479.e410 (2018).
  Article CAS PubMed Google Scholar
• Aoki, T. et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic hodgkin lymphoma. Cancer Discov. 10, 406–421 (2020).
  Article PubMed Google Scholar
• Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789(2019).
  Article CAS PubMed Google Scholar
• Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293–1308 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168, 613–628 (2017).
  Article CAS PubMed Google Scholar
• McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, A. W. et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 173, 1755–1769 (2018).
  Article CAS PubMed Google Scholar
• Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835–849 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Lambrechts, D. et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018).
  Article CAS PubMed Google Scholar
• Andor, N., Maley, C. C. & Ji, H. P. Genomic instability in cancer: teetering on the limit of tolerance. Cancer Res. 77, 2179–2185 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
  Article CAS PubMed Google Scholar
• Li, S. et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat. Med. 22, 792–799 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, D. C. et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 77, 2255–2265 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
  Article CAS PubMed Google Scholar
• Raynaud, F., Mina, M., Tavernari, D. & Ciriello, G. Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability. PLoS Genet. 14, e1007669 (2018).
  Article PubMed PubMed Central Google Scholar
• Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Salmon, H., Remark, R., Gnjatic, S. & Merad, M. Host tissue determinants of tumour immunity. Nat. Rev. Cancer 19, 215–227 (2019).
  CAS PubMed PubMed Central Google Scholar
• Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518, 240–244 (2015).
  Article CAS PubMed Google Scholar
• Keenan, T. E., Burke, K. P. & Van Allen, E. M. Genomic correlates of response to immune checkpoint blockade. Nat. Med. 25, 389–402 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Montesion, M. et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov., CD-20-0672 (2020).
• Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• von Loga, K. et al. Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nat. Commun. 11, 139 (2020).
  Article Google Scholar
• Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019).
  Article CAS PubMed Google Scholar
• Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587, 126–132 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Morris, L. G. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051–10063 (2016).
  Article PubMed PubMed Central Google Scholar
• Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105–113 (2016).
  Article CAS PubMed Google Scholar
• Patten, D. K. et al. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat. Med. 24, 1469–1480 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Ishak, C. A., Classon, M. & De Carvalho, D. D. Deregulation of retroelements as an emerging therapeutic opportunity in cancer. Trends Cancer 4, 583–597 (2018).
  Article CAS PubMed Google Scholar
• Sheffield, N. C. et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat. Med. 23, 386–395 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Gaiti, F. et al. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature 569, 576–580 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Losic, B. et al. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat. Commun. 11, 291 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Ma, K. Y. et al. Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes. JCI Insight 4, e121387 (2019).
  Article PubMed Central Google Scholar
• Suda, K. et al. Innate genetic evolution of lung cancers and spatial heterogeneity: analysis of treatment-naïve lesions. J. Thorac. Oncol. 13, 1496–1507 (2018).
  Article PubMed PubMed Central Google Scholar
• Zhu, J. & Thompson, C. B. Metabolic regulation of cell growth and proliferation. Nat. Rev. Mol. Cell Biol. 20, 436–450 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657–671 (2016).
  Article CAS PubMed Google Scholar
• Xiao, Z., Dai, Z. & Locasale, J. W. Metabolic landscape of the tumor microenvironment at single cell resolution. Nat. Commun. 10, 3763 (2019).
  Article PubMed PubMed Central Google Scholar
• Hensley, C. T. et al. Metabolic heterogeneity in human lung tumors. Cell 164, 681–694 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Hoang-Minh, L. B. et al. Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. EMBO J. 37, e98772 (2018).
  Article PubMed PubMed Central Google Scholar
• Tasdogan, A. et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature 577, 115–120 (2020).
  Article CAS PubMed Google Scholar
• Michealraj, K. A. et al. Metabolic regulation of the epigenome drives lethal infantile ependymoma. Cell 181, 1329–1345(2020).
  Article CAS PubMed Google Scholar
• Sulkowski, P. L. et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature 582, 586–591 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Ocasio, J. et al. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Nat. Commun. 10, 5829 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Bhaduri, A. et al. Outer radial Glia-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell 26, 48–63.e46 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Müller, S. et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 18, 234 (2017).
  Article PubMed PubMed Central Google Scholar
• Bartoschek, M. et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat. Commun. 9, 5150 (2018).
  Article PubMed PubMed Central Google Scholar
• Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268–272 (2018).
  Article CAS PubMed Google Scholar
• van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218–232 (2020).
  Article PubMed PubMed Central Google Scholar
• Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Gerhard, G. M. et al. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J. Exp. Med. 218, e20200264 (2020).
• Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).
  Article Google Scholar
• Batlle, E. & Massagué, J. Transforming growth factor-β signaling in immunity and cancer. Immunity 50, 924–940 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541–550 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).
  Article PubMed Google Scholar
• Maynard, A. et al. Therapy-Induced evolution of human lung cancer revealed by single-cell rna sequencing. Cell 182, 1232–1251(2020).
  Article CAS PubMed PubMed Central Google Scholar
• Bernard, V. et al. Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin. Cancer Res. 25, 2194–2205 (2019).
  Article CAS PubMed Google Scholar
• Mascaux, C. et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature 571, 570–575 (2019).
  Article CAS PubMed Google Scholar
• Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
  Article PubMed PubMed Central Google Scholar
• Jiménez-Sánchez, A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170, 927–938 (2017).
  Article PubMed PubMed Central Google Scholar
• AbdulJabbar, K. et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat. Med. 26, 1054–1062 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25, 1549–1559 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Yan, T. et al. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nat. Commun. 10, 1670 (2019).
  Article PubMed PubMed Central Google Scholar
• Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89–94 (2019).
  Article CAS PubMed Google Scholar
• Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274–278 (2020).
  Article CAS PubMed Google Scholar
• Goveia, J. et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell 37, 21–36 (2020).
  Article CAS PubMed Google Scholar
• Hoadley, K. A. et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 173, 291–304 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Wolf, Y. et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell 179, 219–235 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Russo, M. et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366, 1473–1480 (2019).
  Article CAS PubMed Google Scholar
• Hause, R. J., Pritchard, C. C., Shendure, J. & Salipante, S. J. Classification and characterization of microsatellite instability across 18 cancer types. Nat. Med. 22, 1342–1350 (2016).
  Article CAS PubMed Google Scholar
• Touat, M. et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580, 517–523 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017).
  Article CAS PubMed Google Scholar
• Fang, J. et al. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction. Proc. Natl Acad. Sci. USA 115, 9598–9603 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Jenzer, M. et al. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunol. Immunother. 68, 1621–1633 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Roper, N. et al. APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors. Cell Rep. 26, 2651–2666 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).
• Barthel, F. P. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576, 112–120 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Kedia-Mehta, N. & Finlay, D. K. Competition for nutrients and its role in controlling immune responses. Nat. Commun. 10, 2123 (2019).
  Article PubMed PubMed Central Google Scholar
• Senovilla, L. et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 337, 1678–1684 (2012).
  Article CAS PubMed Google Scholar
• Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765.e716 (2018).
  Article CAS PubMed Google Scholar
• Van den Eynden, J., Jiménez-Sánchez, A., Miller, M. L. & Larsson, E. Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nat. Genet 51, 1741–1748 (2019).
  Article PubMed PubMed Central Google Scholar
• Spranger, S. & Gajewski, T. F. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat. Rev. Cancer 18, 139–147 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the mhc class i antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385–401 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Kitajima, S. et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34–45 (2019).
  Article CAS PubMed Google Scholar
• Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178–193 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160–175.e127 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Su, S. et al. CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172, 841–856 (2018).
  Article CAS PubMed Google Scholar
• Demircioglu, F. et al. Cancer associated fibroblast FAK regulates malignant cell metabolism. Nat. Commun. 11, 1290 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Biffi, G. et al. IL1-induced JAK/STAT signaling Is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282–301 (2019).
  Article PubMed Google Scholar
• Galluzzi, L., Yamazaki, T. & Kroemer, G. Linking cellular stress responses to systemic homeostasis. Nat. Rev. Mol. Cell Biol. 19, 731–745 (2018).
  Article CAS PubMed Google Scholar
• Galluzzi, L. et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J. Immunother. Cancer 8, e000337 (2020).
  Article PubMed PubMed Central Google Scholar
• Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
  Article CAS PubMed Google Scholar
• Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Lemery, S., Keegan, P. & Pazdur, R. First FDA approval agnostic of cancer site — when a biomarker defines the indication. N. Engl. J. Med. 377, 1409–1412 (2017).
  Article PubMed Google Scholar
• Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485–491 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271–1281 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Grasso, C. S. et al. Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov. 8, 730–749 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Vasaikar, S. et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell 177, 1035–1049 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Hellmann, M. D. et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 33, 843–852 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).
  Article CAS PubMed Google Scholar
• Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696–701 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Chowell, D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359, 582–587 (2018).
  Article CAS PubMed Google Scholar
• Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
  Article PubMed PubMed Central Google Scholar
• Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Miao, Y. et al. Adaptive immune resistance emerges from tumor-Initiating stem cells. Cell 177, 1172–1186 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Harel, M. et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell 179, 236–250 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
  Article CAS PubMed Google Scholar
• Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
  Article PubMed PubMed Central Google Scholar
• Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
• Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211 (2019).
  Article CAS PubMed Google Scholar
• Oh, D. Y. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612–1625 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191–1206 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Kamada, T. et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc. Natl Acad. Sci. USA 116, 9999–10008 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12, eaav7431 (2020).
  Article CAS PubMed Google Scholar
• Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1014–1030 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell 37, 471–484 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Vitale, I., Manic, G., Senovilla, L., Kroemer, G. & Galluzzi, L. Karyotypic aberrations in oncogenesis and cancer therapy. Trends Cancer 1, 124–135 (2015).
  Article PubMed Google Scholar
• Sansregret, L., Vanhaesebroeck, B. & Swanton, C. Determinants and clinical implications of chromosomal instability in cancer. Nat. Rev. Clin. Oncol. 15, 139–150 (2018).
  Article CAS PubMed Google Scholar
• Jemaa, M. et al. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death Differ. 20, 1532–1545 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Jones, P. A., Ohtani, H., Chakravarthy, A. & De Carvalho, D. D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 19, 151–161 (2019).
  Article CAS PubMed Google Scholar
• Cascone, T. et al. Increased tumor glycolysis characterizes immune resistance to adoptive t cell therapy. Cell Metab. 27, 977–987 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Renner, K. et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 29, 135–150.e139 (2019).
  Article CAS PubMed Google Scholar
• Andrejeva, G. & Rathmell, J. C. Similarities and distinctions of cancer and immune metabolism in inflammation and tumors. Cell Metab. 26, 49–70 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Bommareddy, P. K., Shettigar, M. & Kaufman, H. L. Integrating oncolytic viruses in combination cancer immunotherapy. Nat. Rev. Immunol. 18, 498–513 (2018).
  Article CAS PubMed Google Scholar
• Gujar, S., Pol, J. G., Kim, Y., Lee, P. W. & Kroemer, G. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends Immunol. 39, 209–221 (2018).
  Article CAS PubMed Google Scholar
• Kepp, O., Marabelle, A., Zitvogel, L. & Kroemer, G. Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies. Nat. Rev. Clin. Oncol. 17, 49–64 (2020).
  Article CAS PubMed Google Scholar
• Zhou, H. et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 7, e2134 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Yamazaki, T. et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 23, 1004–1015 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Yamazaki, T. et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat. Immunol. 21, 1160–1171 (2020).
  Article CAS PubMed Google Scholar
• Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501, 338–345 (2013).
  Article CAS PubMed Google Scholar
• Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I. & Galluzzi, L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat. Immunol. 21, 120–134 (2020).
  Article CAS PubMed Google Scholar
• Yamamoto, T. N., Kishton, R. J. & Restifo, N. P. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat. Med. 25, 1488–1499 (2019).
  Article CAS PubMed Google Scholar
• Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune. Cell Therapies Cell 181, 46–62 (2020).
  CAS PubMed Google Scholar
• June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Slaney, C. Y., Wang, P., Darcy, P. K. & Kershaw, M. H. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 8, 924–934 (2018).
  Article CAS PubMed Google Scholar
• Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341–1355 (2019).
  Article CAS PubMed Google Scholar
• O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).
  Article PubMed PubMed Central Google Scholar
• DeSelm, C. et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol. Ther. 26, 2542–2552 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Godfrey, D. I., Uldrich, A. P., McCluskey, J., Rossjohn, J. & Moody, D. B. The burgeoning family of unconventional T cells. Nat. Immunol. 16, 1114–1123 (2015).
  Article CAS PubMed Google Scholar
• Crowther, M. D. et al. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat. Immunol. 21, 178–185 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Yamaguchi, H. & Hashimoto, K. Association of MR1 protein, an MHC class I-related molecule, with β2-microglobulin. Biochem Biophys. Res. Commun. 290, 722–729 (2002).
  Article CAS PubMed Google Scholar
• DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369–382 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Albrengues, J. et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat. Commun. 6, 10204 (2015).
  Article CAS PubMed Google Scholar
• Sharma, P. & Allison, J. P. Dissecting the mechanisms of immune checkpoint therapy. Nat. Rev. Immunol. 20, 75–76 (2020).
  Article CAS PubMed Google Scholar
• Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D. & Lopez-Soto, A. The hallmarks of successful anticancer immunotherapy. Sci. Transl. Med. 10, eaat7807 (2018).
  Article PubMed Google Scholar
• Quintanal-Villalonga, Á. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360–371 (2020).
  Article PubMed PubMed Central Google Scholar
• Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879–893.e813 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Buque, A. et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat. Commun. 11, 3819 (2020).
  Article CAS PubMed PubMed Central Google Scholar